The conversation discusses hair loss treatments using oral minoxidil, oral dutasteride, and mesotherapy dutasteride, showing impressive 6-month results. The user wishes these treatments were available in the U.S.
The user is mixing various topical solutions for hair loss, including Dutasteride, Minoxidil, Finasteride, tretinoin, RU58841, Stemoxydine, and Reviv AHK-Cu, and is questioning if this practice is effective or wasteful. They are concerned about potential interactions, especially with the new treatment KX-826, which should not be mixed with Minoxidil.
Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
The user had a hair transplant in March 2025 and has been using finasteride since 2023, which halted hair loss but didn't fully restore density. They plan to use dutasteride twice weekly, finasteride five times a week, and saw palmetto to improve hair thickness.
The user is experiencing hair regrowth using topical 0.3% finasteride and 6% minoxidil, with no side effects noted. They are considering switching to oral treatments if progress stalls, but are currently satisfied with the results.
The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.
Users discussed using treatments like minoxidil, finasteride, dutasteride, and exosomes for hair loss. They reported thicker hair and reduced shedding, with some experiencing minor side effects.
The conversation is about how to effectively apply 1mL of a topical hair loss treatment, Pyrilutamide, to cover the entire scalp. One user suggests making a 2.5 mg/mL solution and using 2mL for better coverage.
The conversation is about someone taking dutasteride for hair loss since April 2023 but still experiencing shedding. They had blood tests for various levels and are seeking advice on their DHT levels and vitamin D.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.
A 31-year-old male switched from finasteride to oral dutasteride (0.5mg, 2x a week) and uses liquid minoxidil daily for hair loss. He experienced shedding and regrowth but is considering increasing dutasteride to 3x a week due to concerns about hair density and ongoing issues.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User shares 3.5-month Dutasteride experience, slightly below baseline, with thicker hairs but less density.
The user mixed RU58841 with Minoxidil for hair loss treatment and experienced reduced hair fall and thicker hair but stopped due to chest pain and muscle twitching. They plan to use a new routine without RU58841 or Finasteride due to side effects, including various topical treatments and peptides.
The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.
The conversation discusses mixing finasteride (Essengen-F) with a multi-peptide serum for hair density. The main concern is whether these products can be used together safely.
A user shared their hair progress after three steroid cycles, using 5% minoxidil and 100mg RU58841 daily. They are considering a hair transplant due to paranoia about shedding.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.
Switching from finasteride to dutasteride is discussed, with some users suggesting gradual replacement to potentially improve hair regrowth. OP plans to try replacing one daily use of finasteride with dutasteride to see if it leads to better results.
The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.
Long-term RU58841 users discuss its effectiveness, with some finding it not worth the cost compared to other treatments like Dutasteride and Minoxidil. One user experienced side effects from a chemical company product, while another is regrowing hair after stopping RU58841.
This user experienced improvements in their hair density and texture through the use of finasteride (1.25mg) and minoxidil (5%) applied topically once a day over 8 months, with no reported side effects other than slightly lowered libido.
The user has been taking 0.5 finasteride for 10 months and wants to repeat blood tests, including estradiol. However, their doctor is reluctant to test estradiol, arguing it's typically low in men, and the user is considering seeking a second opinion.